Introduction. Transdermal delivery of medicinal substances is based on the penetration of the active pharmaceutical ingredient through the intact skin, its further entry into the systemic bloodstream and, thereafter, to the target organ. Currently, gels, ointments, emulsions and transdermal therapeutic systems (transdermal patches) are used as transdermal agents. Transdermal patches are able to provide a target constant concentration of medicinal substances in blood plasma for a long time (from 1 to 7 days). Transdermal delivery has a number of advantages: increased bioavailability of medicinal substances due to the elimination of losses associated with metabolism in the gastrointestinal tract and in the liver; reducing the risk of adverse reactions which can be caused by leveling of concentration jumps of the medicinal substances in the blood; painlessness and convenience; possibility to change the dose by varying the area of the patch and the duration of use; possibility to stop the treatment at any time, etc. For patients with chronic diseases requiring constant repeated oral administration of drugs, suffering from dysphagia and diseases of the gastrointestinal tract, the transdermal route of administration is the most optimal. In some cases, when the patient is unconscious, suffers from sclerosis, or has impaired vital functions (for example, the ability to breathe and swallow independently), transdermal delivery is optimal and in some cases is the only alternative. Purpose. To analyze the current range of drugs for transdermal delivery, to assess the role and prospects of using transdermal delivery in the treatment of cardiovascular diseases. Methods. The search for literary data was carried out using the PubMed and Google search engines among Russian – and English-language original articles. The search of registered drugs in the form of transdermal patches was carried out using drugs registries of the United States and other countries. When searching, the terms «transdermal delivery», «transdermal patch», «bisoprolol», «clopidogrel», «transdermal delivery», «transdermal patch» were used. Conclusion. In the global pharmaceutical market, transdermal delivery is used for a limited number of medicinal substances of different pharmacotherapeutic groups, of which only three medicinal substances (nitroglycerin, clonidine, bisoprolol) are used in the treatment of cardiovascular diseases. Many attempts have been made to obtain and evaluate transdermal patches with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, antiplatelet agents used in the treatment of cardiovascular diseases, but the volume of these studies is insufficient for registration and clinical use.
keywords: transdermal delivery, transdermal patch, bisoprolol, clopidogrel
for references: N.S. Golyak. Transdermal delivery of drugs and its role in therapy of cardiovascular diseases. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2020, vol. 4, no. 2, pp. 1057–1062
1. U.S. Transdermal Drug Delivery System Market Size, Share & Trends Analysis Report By Technology (Active, Passive), By Application (Hormone, Cardiovascular, Neurodegenerative, CNS, Pain Management), And Segment Forecasts, 2019-2026. Available at: https://www.grandviewresearch.com/industry-analysis/us-transdermaldrug-delivery-system-market. (accessed 30.09.2020).
2. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm. (accessed 30.09.2020).
3. Tamura G., Ichinose M., Fukuchi Y., Miyamoto M. Transdermal Tulobuterol Patch, a Long-Actingβ2-Agonist. Allergol Int, 2012, vol. 61, no. 2, pp. 219-229.
4. Matsuoka H., Kuwajima I., Shimada K., Mitamura H., Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J of Clin Hypertens, 2013, vol. 15, no. 11, pp. 806-814.
5. Yamashita T., Ikeda T., Akita Y. Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). J Cardiol, 2019, vol. 73, no. 5, pp. 386-393.
6. Momomura S.I., Saito Y., Yasumura Y., Yamamoto K., Sakata Y., Daimon M., Kinugawa K., Okamoto H., Dohi N., Komuro I. Efficacy and safety of switching from oral bisoprolol to transdermal patch in japanese patients with chronic heart failure. Circ J, 2017, vol. 82, no. 1, pp. 141-147.
7. Kiuchi S., Hisatake S., Kabuki T., Oka T., Dobashi S., Fujii T., Sano T., Ikeda T. Bisoprolol transdermal patch improves orthostatic hypotension in patients with chronic heart failure and hypertension. Clin Exp Hypertens., 2020, vol. 42, no. 6, pp. 539-544.
8. Gosudarstvenny’y reestr lekarstvenny’h sredstv Rossiyskoy Federacii [State register of medicinal products of the Russian Federation]. Available at: http://grls. rosminzdrav.ru/GRLS.aspx. (accessed 01.09.2020). (in Russian).
9. Reestr lekarstvenny’h sredstv Respubliki Belarus’ [Register of medicines of the Republic of Belarus]. Available at: http://rceth.by/Refbank/. (accessed 01.09.2020). (in Russian).
10. Pastore M., Kalia Y., Horstmann M., Roberst M. Transdermal patches: history, development and pharmacology. Br J Pharmacol, 2015, vol. 172, no. 9, pp. 2179-2209.
11. Ita K. Transdermal delivery of drugs with microneedles: strategies and outcomes. J Drug Deliv Sci Technol, 2015, vol. 29, pp. 16-23.
12. Ita K. The potential use of transdermal drug delivery for the prophylaxis and management of stroke and coronary artery disease. Pharmacol Rep, 2017, vol. 69, no. 6, pp. 1322-1327.
13. Tanwar H., Sachdeva R. Transdermal drug delivery system: A review. Int J Pharm Sci, 2016, vol. 7, pp. 2274-2290.
14. Shams M.S., Alam M.I., Ali A., Sultana Y., Aqil M., Shakeel F. Pharmacokinetics of a losartan potassium released from a transdermal therapeutic system for the treatment of hypertension. Pharmazie, 2010, vol. 65, no. 9, pp. 679-682.
15. Rokade M.M., Thakare P.R., Rupvate S.R., et al. Formulation design and evaluation of transdermal film of losartan potassium using hydrophilic and hydrophobic polymers. Am J Pharm Tech Res, 2012, vol. 2, pp. 771-781.
16. Nishida N., Taniyama K., Sawabe T., Manome Y. Development and evaluation of a monolithic drug-in-adhesive patch for valsartan. Int J Pharm, 2010, vol. 402, no. 1-2, pp. 103-109.
17. Mittal S., Mittal A., Sharma K., Alam S. Proniosomes as a drug carrier for transdermal delivery of candesartan cilexetil. Int J Nano Studies Tech, 2013, vol. 2, pp. 201-207.
18. Helal F., Lane M.E. Transdermal delivery of angiotensin converting enzyme inhibitors. Eur J Pharm Biopharm, 2014, vol. 88, no. 1, pp. 1-7. doi: 10.1016/j.ejpb.2014.03.007.
19. Aqil M., Bhavna, Chowdhary I., Sultana Y., Talegaonkar S., Ahmad F.J., Ali M.M. Transdermal therapeutic system of enalapril maleate using piperidine as penetration enhancer. Curr Drug Deliv, 2008, vol. 5, no. 2, pp. 148-152.
20. Banweer J., Pandey S., Pathak A.K. Formulation, optimization and evaluation of matrix type transdermal system of lisinopril dehydrate using permeation enhancers. Drug Invent Today, 2010, vol. 2, no. 2, pp. 134-137.
21. Subramanian S., Senith S.K. Formulation and evaluation of Clopidogrel bisulfate loaded transdermal patches for anti-platelet activity. Int J Res Pharm Sci, 2018, vol. 9, no. 1, pp. 25-29.
22. Dwarakanadha R.P., Swarnalatha D., Sidda R.B., Karthik S.K.P, Sardar U.M. Design: development and characterization of clopidogrel bisulfate transdermal drug delivery system. Asian J Pharm Clin Res, 2015, vol. 8, no. 2, pp. 277-280.
23. Ammar H., Ghorab M., El-Nahhas, Kamel R. Design of a transdermal system for aspirin as antithrombotic drug. Int J Pharm, 2006, vol. 327, no. 1-2, pp. 81-88.
24. Shamsher A., Charoo N., Kohli K., Pillai K., Rahman Z. Effect of Transdermally Delivered Aspirin on Blood. Coagulation Parameters. Am J Biomed Sci, 2010, vol. 2, no. 2, pp. 129-141. doi: 10.5099/aj100200129.